NCT04291781View on ClinicalTrials.gov

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

May 20, 2021

Study Completion Date

May 20, 2021

Conditions
Primary IgA Nephropathy
Interventions
BIOLOGICAL

RC18 160mg

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

BIOLOGICAL

RC18 240mg

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

BIOLOGICAL

placebo

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

Trial Locations (1)

100010

Peking University First Hospital., Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04291781 - A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy | Biotech Hunter | Biotech Hunter